{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:17:35Z","timestamp":1787980655387,"version":"build-2784847793"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Among 1069 people with HIV-1 and mild to moderate renal impairment at baseline treated with bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) across 9 clinical trials, renal function remained generally stable over follow-up of up to 240 weeks. Renal adverse events were infrequent, and discontinuation due to renal toxicity was rare.<\/jats:p>","DOI":"10.1093\/ofid\/ofag265","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:12:15Z","timestamp":1777637535000},"source":"Crossref","is-referenced-by-count":1,"title":["Renal Outcomes in People With HIV-1 and Renal Impairment Treated With Bictegravir\/Emtricitabine\/Tenofovir Alafenamide: Integrated Analysis From 9 Phase 3\/3b Clinical Trials"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2844-1612","authenticated-orcid":false,"given":"Frank A","family":"Post","sequence":"first","affiliation":[{"name":"Department of Inflammation Biology, School of Immunology & Microbial Sciences, King's College Hospital NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7764-0212","authenticated-orcid":false,"given":"David","family":"Wohl","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of North Carolina , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1267-4347","authenticated-orcid":false,"given":"Geoffroy","family":"Liegeon","sequence":"additional","affiliation":[{"name":"Saint-Louis Hospital, AP-HP, Universit\u00e9 Paris Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0568-6457","authenticated-orcid":false,"given":"Indira","family":"Brar","sequence":"additional","affiliation":[{"name":"Infectious Disease, Henry Ford Health , Detroit, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7478-7609","authenticated-orcid":false,"given":"Debbie","family":"Hagins","sequence":"additional","affiliation":[{"name":"Chatham CARE Center , Savannah, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2402-643X","authenticated-orcid":false,"given":"Yazdan","family":"Yazdanpanah","sequence":"additional","affiliation":[{"name":"Bichat\u2013Claude Bernard Hospital, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchalee","family":"Avihingsanon","sequence":"additional","affiliation":[{"name":"HIV-NAT, Thai Red Cross AIDS Research Centre , Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Development, Gilead Sciences, Inc. , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2763-8745","authenticated-orcid":false,"given":"Keith","family":"Aizen","sequence":"additional","affiliation":[{"name":"Clinical Development, Gilead Sciences, Inc. , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-3423","authenticated-orcid":false,"given":"Jason T","family":"Hindman","sequence":"additional","affiliation":[{"name":"Clinical Development, Gilead Sciences, Inc. , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Indiana University School of Medicine , Indianapolis, Indiana ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"2026052111172388800_ofag265-B1","author":"US Department of Health and Human Services"},{"key":"2026052111172388800_ofag265-B2","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIRCRESAHA.124.323948","article-title":"Cardiac and renal comorbidities in aging people living with HIV","volume":"134","author":"McCutcheon","year":"2024","journal-title":"Circ Res"},{"key":"2026052111172388800_ofag265-B3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/infdis\/jiaa125","article-title":"Changes in renal function after switching from TDF to TAF in HIV-infected individuals: a prospective cohort study","volume":"222","author":"Surial","year":"2020","journal-title":"J Infect Dis"},{"key":"2026052111172388800_ofag265-B4","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/QAD.0000000000002223","article-title":"Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials","volume":"33","author":"Gupta","year":"2019","journal-title":"AIDS"},{"key":"2026052111172388800_ofag265-B5","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1016\/S2352-3018(23)00151-0","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial","volume":"10","author":"Avihingsanon","year":"2023","journal-title":"Lancet HIV"},{"key":"2026052111172388800_ofag265-B6","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","article-title":"Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial","volume":"5","author":"Daar","year":"2018","journal-title":"Lancet HIV"},{"key":"2026052111172388800_ofag265-B7","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"2026052111172388800_ofag265-B8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/QAI.0000000000002137","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide (B\/F\/TAF) in virologically suppressed HIV-1 infected women: a randomized, open-label, multicenter, active-controlled, phase 3, noninferiority trial","volume":"82","author":"Kityo","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026052111172388800_ofag265-B9","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"2026052111172388800_ofag265-B10","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","article-title":"Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus","volume":"73","author":"Sax","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026052111172388800_ofag265-B11","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"2026052111172388800_ofag265-B12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/QAI.0000000000002731","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide in black Americans with HIV-1: a randomized phase 3b, multicenter, open-label study","volume":"88","author":"Hagins","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026052111172388800_ofag265-B13","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s40121-021-00419-5","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in virologically suppressed people with HIV aged &gt;\/= 65 years: week 48 results of a phase 3b, open-label trial","volume":"10","author":"Maggiolo","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2026052111172388800_ofag265-B14","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"2026052111172388800_ofag265-B15","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration","volume":"371","author":"D:A:D Study Group","year":"2008","journal-title":"Lancet"},{"key":"2026052111172388800_ofag265-B16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"2026052111172388800_ofag265-B17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijid.2019.07.011","article-title":"Virologically suppressed HIV-infected patients on TDF-containing regimens significantly benefit from switching to TAF-containing regimens: a meta-analysis of randomized controlled trials","volume":"87","author":"Tao","year":"2019","journal-title":"Int J Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag265\/68205227\/ofag265.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/5\/ofag265\/68205227\/ofag265.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/5\/ofag265\/68205227\/ofag265.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:17:29Z","timestamp":1779376649000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag265\/8666707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag265","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,28]]},"article-number":"ofag265"}}